FDA Plays Both Sides
Drug and device makers have started testing a simple but potentially powerful argument when their customers wind up hurt.
In a nutshell, they say this: It's not our fault. The Food and Drug Administration approved our products and deemed them safe for public use. A blessing from the FDA, which boasts a slew of medical experts, trumps your lawsuit any day.
In a twisted deal, critics claim, the FDA has stacked the deck against the very people it is supposed to protect. Early this year, the agency announced long-awaited labeling changes meant to better explain drugs and their side effects. But before issuing its new guidelines, the agency quietly added a preamble that could give its own stamp of approval more power than state laws allowing consumers to sue drug makers for failing to warn them of possible risks. Judges must now decide whether the rule applies to those cases or not.
Daniel Troy, former chief counsel of the FDA, explained the so-called Preemption Preamble in a recent issue of Legal Times."The FDA's bottom-line concern is that 'state-law attempts to impose additional warnings can lead to labeling that does not accurately portray a product's risks, thereby potentially discouraging safe and effective use of approved drugs,'" Troy wrote in the magazine's Oct. 9 issue. "A few courts have refused to defer to the Preemption Preamble and have rejected preemption on a variety of grounds. But few, if any, of those decisions carefully analyze the nature and extent of the FDA's decision-making or the degree of deference due to the FDA's views."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV